4516

Nippon Shinyaku Co.,Ltd.

日本新薬株式会社
Pharmaceutical
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
← Companies
Price
¥4,201
Market Cap
¥283.1B
Ent. Value
—
Net Cash est
—
Shares Out.
67.4M
P / E
8.7×
EV / EBIT
—
P / Book
—
P / NCAV
2.50×
Div. Yield
2.95%
Financials
Metric FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥160.2B ¥148.3B ¥144.2B ¥137.5B
Cost of Sales ¥51.1B ¥50.2B ¥56.0B ¥50.2B
Gross Profit ¥109.1B ¥98.0B ¥88.2B ¥87.3B
SG&A ¥38.0B ¥35.0B ¥34.8B ¥32.2B
Operating Income ¥35.5B ¥33.3B ¥30.0B ¥32.9B
Non-Operating Income ¥830M ¥650M ¥575M ¥472M
Interest Income — — — ¥17M
Non-Operating Expenses ¥145M ¥329M ¥136M ¥119M
Interest Expense — — — ¥55M
Pre-tax Income ¥36.1B ¥33.6B ¥30.5B ¥33.3B
Net Income (owners) ¥32.6B ¥25.9B ¥22.8B ¥25.0B
Minority Interest ¥2M ¥2M ¥7M ¥12M
Comprehensive Income ¥35.1B ¥32.6B ¥22.9B ¥24.2B
EBITDA ¥41.5B ¥38.3B ¥35.1B ¥37.5B
EPS ¥483.40 ¥383.82 ¥338.70 ¥342.14
Shares Outstanding 67.4M 67.4M 67.4M 67.4M
Shares Issued (total) 70.3M 70.3M 70.3M 70.3M
Treasury Shares 2.9M 2.9M 2.9M 2.9M